Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H29NO3.ClH |
Molecular Weight | 415.953 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=C(C=C1OC)C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)C2
InChI
InChIKey=XWAIAVWHZJNZQQ-UHFFFAOYSA-N
InChI=1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H
Molecular Formula | C24H29NO3 |
Molecular Weight | 379.492 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Donepezil, marketed under the trade name Aricept, is a medication used in the palliative treatment of Alzheimer's disease. Aricept is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy
has been demonstrated in patients with mild to moderate Alzheimer’s Disease, as well
as in patients with severe Alzheimer’s Disease. Donepezil is postulated to exert its therapeutic effect by enhancing
cholinergic function. This is accomplished by increasing the concentration of
acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
6.7 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ARICEPT Approved UseDonepezil hydrochloride orally disintegrating tablets, USP are an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's Disease (1). Donepezil hydrochloride orally disintegrating tablets, USP are indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760 |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DONEPEZIL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
60.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760 |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DONEPEZIL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2889.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760 |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DONEPEZIL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5051.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760 |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DONEPEZIL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
72.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760 |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DONEPEZIL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
73.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760 |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DONEPEZIL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760 |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DONEPEZIL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9839760 |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DONEPEZIL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
175 mg single, transdermal Dose: 175 mg Route: transdermal Route: single Dose: 175 mg Sources: |
healthy, 24.9±3.3 years n = 9 Health Status: healthy Age Group: 24.9±3.3 years Sex: M Population Size: 9 Sources: |
|
175 mg 1 times / 3 days steady, transdermal Dose: 175 mg, 1 times / 3 days Route: transdermal Route: steady Dose: 175 mg, 1 times / 3 days Sources: |
healthy, 24.9±3.3 years n = 9 Health Status: healthy Age Group: 24.9±3.3 years Sex: M Population Size: 9 Sources: |
|
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Disc. AE: Bradycardia, Diarrhea... AEs leading to discontinuation/dose reduction: Bradycardia (0.7%) Sources: Page: p. 50Diarrhea (1.7%) Nausea (1.9%) Vomiting (2.9%) QT interval prolonged (0.4%) Anorexia (0.3%) Dizziness (1.1%) Headache (0.4%) Somnolence (0.6%) Syncope (0.2%) Aggression (0.5%) Agitation (0.8%) Confusional state (0.7%) |
50 mg single, oral Overdose |
unhealthy, 79 years n = 1 Health Status: unhealthy Condition: Alzheimer disease Age Group: 79 years Sex: F Population Size: 1 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (1 patient) Sources: Vomiting (1 patient) Bradycardia (1 patient) |
30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, 80 years n = 1 Health Status: unhealthy Condition: Alzheimer disease Age Group: 80 years Sex: F Population Size: 1 Sources: |
Disc. AE: Myoclonus... AEs leading to discontinuation/dose reduction: Myoclonus (1 patient) Sources: |
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 315 Health Status: unhealthy Age Group: adult Population Size: 315 Sources: |
Other AEs: Diarrhea, Nausea... Other AEs: Diarrhea (3%) Sources: Nausea (3%) Vomiting (2%) |
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult n = 350 Health Status: unhealthy Age Group: adult Population Size: 350 Sources: |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (<1%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Syncope | 0.2% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Anorexia | 0.3% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Headache | 0.4% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
QT interval prolonged | 0.4% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Aggression | 0.5% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Somnolence | 0.6% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Bradycardia | 0.7% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Confusional state | 0.7% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Agitation | 0.8% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Dizziness | 1.1% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Diarrhea | 1.7% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Nausea | 1.9% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Vomiting | 2.9% Disc. AE |
23 mg 1 times / day steady, oral Dose: 23 mg, 1 times / day Route: oral Route: steady Dose: 23 mg, 1 times / day Sources: Page: p. 50 |
unhealthy, 73.9 years n = 967 Health Status: unhealthy Condition: Alzheimer disease Age Group: 73.9 years Sex: M+F Population Size: 967 Sources: Page: p. 50 |
Bradycardia | 1 patient | 50 mg single, oral Overdose |
unhealthy, 79 years n = 1 Health Status: unhealthy Condition: Alzheimer disease Age Group: 79 years Sex: F Population Size: 1 Sources: |
Nausea | 1 patient | 50 mg single, oral Overdose |
unhealthy, 79 years n = 1 Health Status: unhealthy Condition: Alzheimer disease Age Group: 79 years Sex: F Population Size: 1 Sources: |
Vomiting | 1 patient | 50 mg single, oral Overdose |
unhealthy, 79 years n = 1 Health Status: unhealthy Condition: Alzheimer disease Age Group: 79 years Sex: F Population Size: 1 Sources: |
Myoclonus | 1 patient Disc. AE |
30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, 80 years n = 1 Health Status: unhealthy Condition: Alzheimer disease Age Group: 80 years Sex: F Population Size: 1 Sources: |
Vomiting | 2% | 10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 315 Health Status: unhealthy Age Group: adult Population Size: 315 Sources: |
Diarrhea | 3% | 10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 315 Health Status: unhealthy Age Group: adult Population Size: 315 Sources: |
Nausea | 3% | 10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 315 Health Status: unhealthy Age Group: adult Population Size: 315 Sources: |
Diarrhea | <1% Disc. AE |
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult n = 350 Health Status: unhealthy Age Group: adult Population Size: 350 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Donepezil hydrochloride: a treatment drug for Alzheimer's disease. | 2001 |
|
Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? | 2001 |
|
The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. | 2001 |
|
EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. | 2001 |
|
Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. | 2001 Aug |
|
Medications for the treatment of Alzheimer's disease. | 2001 Aug |
|
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. | 2001 Aug 14 |
|
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. | 2001 Aug 28 |
|
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. | 2001 Dec |
|
Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease. | 2001 Dec |
|
Unsafe prescription medication switching recommendations. | 2001 Dec |
|
Donepezil in schizophrenia--is it helpful? An experimental design case study. | 2001 Dec |
|
Alzheimer's disease: recent advances in etiology, diagnosis, and management. | 2001 Dec |
|
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko]. | 2001 Dec 13 |
|
[A patient with probable dementia with Lewy bodies, who showed improvement of dementia and parkinsonism by the administratim of donepezil]. | 2001 Jul |
|
Featured CME topic: dementia. Medication update. | 2001 Jul |
|
Newest developments in dementia treatment and prevention. | 2001 Jul-Aug |
|
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. | 2001 Jul-Sep |
|
Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. | 2001 Nov |
|
[Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies]. | 2001 Nov |
|
Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target. | 2001 Nov |
|
Equity in the new NHS. Evidence cannot help in all situations. | 2001 Nov 10 |
|
SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. | 2001 Nov 16 |
|
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]. | 2001 Nov 29 |
|
Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrroles related to donepezil. | 2001 Nov 8 |
|
[Risperidone in the ambulatory treatment of behavior disorders in demented patients of Alzheimer's type: a retrospective analysis]. | 2001 Nov-Dec |
|
A case of Korsakoff's syndrome improved by high doses of donepezil. | 2001 Nov-Dec |
|
Treatment of tardive dyskinesia with donepezil: a pilot study. | 2001 Oct |
|
[Effectiveness of donepezil on several cognitive functions in patients with Alzheimer's disease over 12 months]. | 2001 Oct |
|
Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. | 2001 Oct |
|
[Relief for caregivers. Anti-dementia drug saves costs]. | 2001 Oct 18 |
|
Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. | 2001 Winter |
|
Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. | 2002 |
|
Donepezil management of schizophrenia with associated dementia. | 2002 Apr |
|
Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety. | 2002 Feb |
|
Feasibility of vascular dementia treatment with cholinesterase inhibitors. | 2002 Feb |
|
Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease. | 2002 Feb 8 |
|
[Pharmacotherapy for the treatment of Alzheimer's disease--the present state and the development in the future]. | 2002 Jan |
|
A new HPLC method to determine Donepezil hydrochloride in tablets. | 2002 Jan 1 |
|
[Alzheimer dementia. Intervening as early as possible]. | 2002 Jan 17 |
|
Therapeutic effects of an acetylcholinesterase inhibitor (donepezil) on memory in Wernicke-Korsakoff's disease. | 2002 Jan-Feb |
|
Lewy body dementia: case report and discussion. | 2002 Jan-Feb |
|
How many patients complete an adequate trial of donepezil? | 2002 Jan-Mar |
|
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study. | 2002 Mar |
|
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. | 2002 Mar |
|
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. | 2002 Mar 1 |
|
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. | 2002 Mar 12 |
|
Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. | 2002 Mar 5 |
|
In vitro toxicity of rivastigmine and donepezil in cells of epithelial origin. | 2002 Mar-Apr |
|
Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease. | 2002 Mar-Apr |
Sample Use Guides
Mild to Moderate Alzheimer’s Disease - 5 mg or 10 mg
administered once daily
Moderate to Severe Alzheim er’s Disease - 10 mg or 23 mg
administered once daily
A dose of 10 mg once daily can be administered once patients have been
on a daily dose of 5 mg for 4 to 6 weeks. A dose of 23 mg once daily can
be administered once patien ts have been on a dose of 10 mg once daily
for at least 3 months
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16570913
Donepezil inhibited freshly prepared human erythrocyte AChE with IC50 22 nM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:20 GMT 2023
by
admin
on
Fri Dec 15 15:31:20 GMT 2023
|
Record UNII |
3O2T2PJ89D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
BALAXUR (REFUSED: ALZHEIMER DISEASE)
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
ACRESCENT (REFUSED: ALZHEIMER DISEASE)
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
||
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
737535
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
3O2T2PJ89D
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
3O2T2PJ89D
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
4696
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL502
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
5741
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
100000091200
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
m4738
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT000938
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
758882
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
SUB13647MIG
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
HH-52
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
1224981
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
C2603
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
120011-70-3
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | |||
|
236559
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID0046698
Created by
admin on Fri Dec 15 15:31:20 GMT 2023 , Edited by admin on Fri Dec 15 15:31:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Procedure 2
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Procedure 2
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|